Portugal A staunch advocate for diversity and inclusion, Helena Freitas today leads the Portuguese affiliate of Sanofi, consistently ranked among the leading pharmaceutical firms in the country. With a focus on growth in the hospital setting as well as addressing the high incidence of diabetes in Portugal, Freitas is confident of…
Egypt AbbVie’s GM for Egypt & Levant, Ali Sleiman, explains the factors behind the stellar growth that has made the cluster one of the company’s fastest-growing global markets in 2021. He also discusses the favourable environment created by Egypt’s healthcare reforms and how they have quickened regulatory approvals and access, leading…
Italy Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of the COVID-19 pandemic and how it not only put Pfizer in the spotlight but also triggered an unprecedented dialogue between…
Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…
Spain Dr Manel Juan is part of the team behind the development of the first European CAR-T-cell therapy to treat multiple myeloma, the second most common type of blood cancer. As head of immunology at the Hospital Clinic Barcelona, he walks us through his personal journey with the project, the challenges…
Singapore ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead asset has the potential to compete with Sanofi’s blockbuster Dupixent and why ASLAN decided to delist from the Taiwan Stock…
China HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in microbial engineering and chemical engineering and a PhD in molecular biology and genetics, an academic career at top US institutions…
China Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders. The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer…
Tunisia Salim Ouertani, business unit manager at AbbVie Tunisia, has been with the affiliate since its beginning in Tunisia when it was spun-off from Abbott in 2013, being in charge of ensuring a smooth transition. Presently, AbbVie’s manager runs ethical operations and is looking forward to supporting more patients suffering from…
Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…
Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…
immunology The executive director of the university spin-off UDIMEB explains the major achievements of the institution, her plans to convert it into a strategic partner to the pharmaceutical and biotechnology industry to conduct pre-clinical tests and the challenges spin-off initiatives face today in Mexico. In the past pharmaceutical R&D activities…
See our Cookie Privacy Policy Here